MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/1748-717x-7-85

Медицинская библиотека · Radiation oncology (London, England) · 2012

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment.

Lee Dong Soo, Kim Yeon Sil, Cheon Jae Seok, Song Jin Ho, Son Seok Hyun, Jang Ji Sun, Kang Young Nam, Kang Jing Hyoung, Jung So Lyoung, Yoo Ie Ryung, Jang Hong Seok

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The aim of this study was to report the long-term clinical outcomes of patients who received stereotactic body radiotherapy (SBRT) as a boost treatment for head and neck cancer.

MATERIALS AND

METHODS

Between March 2004 and July 2007, 26 patients with locally advanced, medically inoperable head and neck cancer or gross residual tumors in close proximity to critical structures following head and neck surgery were treated with SBRT as a boost treatment. All patients were initially treated with standard external beam radiotherapy (EBRT). SBRT boost was prescribed to the median 80% isodose line with a median dose of 21 (range 10-25) Gy in 2-5 (median, 5) fractions.

RESULTS

The median follow-up after SBRT was 56 (range 27.6 - 80.2) months. The distribution of treatment sites in 26 patients was as follows: the nasopharynx, including the base of the skull in 10 (38.5%); nasal cavity or paranasal sinus in 8 (30.8%); periorbit in 4 (15.4%); tongue in 3 (11.5%); and oropharyngeal wall in 1 (3.8%). The median EBRT dose before SBRT was 50.4 Gy (range 39.6 - 70.2). The major response rate was 100% with 21 (80.8%) complete responses (CR). Severe (grade ≥ 3) late toxicities developed in 9 (34.6%) patients, and SBRT boost volume was a significant parameter predicting severe late complication.

CONCLUSIONS

The present study demonstrates that a modern SBRT boost is a highly efficient tool for local tumor control. However, we observed a high frequency of serious late complications. More optimized dose fractionation schedule and patient selection are required to achieve excellent local control without significant late morbidities in head and neck boost treatment.

Для цитирования: Lee Dong Soo, Kim Yeon Sil, Cheon Jae Seok, Song Jin Ho, Son Seok Hyun, Jang Ji Sun, Kang Young Nam, Kang Jing Hyoung, Jung So Lyoung, Yoo Ie Ryung, Jang Hong Seok. Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment.. Radiation oncology (London, England). 2012. DOI: 10.1186/1748-717x-7-85.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.